TG Therapeutics (OTCMKTS:TGTX) Releases Earnings Results, Beats Estimates By $2.22 EPS

TG Therapeutics (OTCMKTS:TGTX) issued its earnings results on Monday. The company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $2.22, RTT News reports. During the same quarter in the prior year, the business posted $0.02 EPS.

TG Therapeutics Trading Down 3.1%

TG Therapeutics stock opened at $33.69 on Tuesday. TG Therapeutics has a 52-week low of $22.92 and a 52-week high of $46.48. The firm has a market cap of $5.35 billion, a P/E ratio of 91.05 and a beta of 1.97.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.